MetaVia Inc. — Director's Dealing 2023

Jul 28, 2023

SEC Form 4/A — Form 4/A

Issuer: NeuroBo Pharmaceuticals, Inc. (NRBO)
CIK: 0001638287
Period of Report: 2022-07-26

Reporting Person: Kim Na Yeon (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-26	Common Stock	J	4671	—	Acquired	4671	Indirect

Footnotes

F1: This amendment is being filed to add the acquisition of 4,671 shares by E&Investment Inc., which was inadvertently left off the original Form 4.

F2: E&Investment Inc. received a pro rata distribution from E&Healthcare Investment Fund II, of which the reporting person is a limited partner, for no consideration.

F3: The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock.

F4: Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.